Generalized erythroderma and palmoplantar hyperkeratosis in a patient receiving TNF‐alpha antagonist therapy
Generalized erythroderma and palmoplantar hyperkeratosis in a patient receiving TNF‐alpha antagonist therapy
复制标题
接受 TNF-α 拮抗剂治疗的患者出现全身性红皮病和掌跖角化过度
DOI：
10.1111/cup.12188
复制
发表时间：
2013
影响因子：
1.7
通讯作者：
J. Auboeck
中科院分区：
文献类型：
--
作者：
Karin M. Dunst‐Huemer;C. Scheurecker;J. Auboeck
To the Editor, We read with great interest the recent article regarding adverse cutaneous eruptions in patients receiving tumor necrosis factor (TNF)-α antagonists.1 The authors reported on adverse skin eruptions in six patients receiving anti-TNF-alpha therapies with either infliximab, adalimumab or etanercept. They defined a variety of cutaneous pathologies, including pustular folliculitis, psoriasiform drug eruption, palmoplantar pustular psoriasis, interface dermatitis (erythema multiforme-like hypersensitivity reaction), neutrophilic eccrine hidradenitis, Sweet syndrome, drug-induced lupus-like syndrome and leukocytoclastic vasculitis. Of these, neutrophilic eccrine hidradenitis and Sweet syndrome-like hypersensitivity reactions were described for the first time in the literature. We wish to expand on the variety of cutaneous eruptions encountered after biologic therapy using TNF-alpha antagonists by reporting on a patient with generalized erythroderma and palmoplantar hyperkeratosis after treatment with adalimumab for psoriasis vulgaris. A 62-year-old male patient was treated at our department for long-standing psoriasis vulgaris. Owing to non-responsiveness to psoralen ultraviolet (UV)-A therapy, narrowband UV-B therapy and acitretin, therapy with adalimumab was initiated. Approximately 5 weeks after initiation of treatment with this agent, the patient developed generalized erythroderma (Fig. 1) showing erythema with severe inflammation and prominent scaling affecting almost the entire integument and accompanied by severe palmoplantar hyperkeratosis (Fig. 2). Fig. 1. Five weeks after initiation of treatment with adalimumab for psoriasis, the patient developed generalized severe erythroderma.
